CompletedNCT05227690
This study exists to compare options and see whether the medication CVL-231 offers something meaningfully different. Researchers are trying to understand how people respond to the medication CVL-231 in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, United States
- Sponsor
- AbbVie
- Condition
- Schizophrenia
CompletedNCT05165654
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
- Condition
- Schizophrenia
CompletedNCT04820309
This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
TerminatedNCT06374290
This study exists to see whether the medication Injectable is workable and worth testing more broadly. Researchers are trying to understand how people respond to the medication Injectable in practice and what may need to be adjusted.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
- Condition
- Schizophrenia
CompletedNCT03681145
This study exists to see whether acceptance and commitment therapy, a talking treatment, is workable and worth testing more broadly. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can work better when mental health difficulties overlap with substance use.
DepressionOtherFrom 18 Years to 29 Years
- Countries
- United States
- Sponsor
- University of California, San Francisco
- Condition
- Depression
CompletedNCT03314129
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- University of Rochester
- Condition
- Schizophrenia
TerminatedNCT03121586
This study exists to understand how the medication Pimavanserin holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherOver 18 Years
- Countries
- Argentina, Bulgaria, Canada, Croatia, Czech Republic, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Ukraine, United States
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
CompletedNCT04325386
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 22 Years to 85 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT01490086
This study exists to understand whether this type of care is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- India, Malaysia, Moldova, Philippines, United States
- Sponsor
- Reviva Pharmaceuticals
- Condition
- Schizophrenia
CompletedNCT00373672
This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Northwestern University
- Condition
- Schizophrenia
CompletedNCT05686239
This study exists to compare options and see whether the medication RL-007 offers something meaningfully different. Researchers are trying to understand whether the medication RL-007 can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Bulgaria, Czech Republic, Poland, United States
- Sponsor
- Recognify Life Sciences
- Condition
- Schizophrenia
CompletedNCT05905601
This study exists to see whether psychoeducation, a guided learning and support program, is workable and worth testing more broadly. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 30 Years
- Countries
- United States
- Sponsor
- University of Washington
- Condition
- Schizophrenia
CompletedNCT03814967
This study exists to compare options and see whether brain scans or other body measurements offers something meaningfully different. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- United States
- Sponsor
- University of California, Davis
- Condition
- Schizophrenia
CompletedNCT05443724
This study exists to understand how the medication CVL-231 holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Bulgaria, Hungary, United States, Ukraine
- Sponsor
- AbbVie
- Condition
- Schizophrenia
CompletedNCT03708315
This study exists to better understand the safety of a medication treatment and how manageable it feels in practice. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Yale University
- Condition
- Schizophrenia
CompletedNCT05438160
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- United States
- Sponsor
- Click Therapeutics, Inc.
- Condition
- Schizophrenia
CompletedNCT03034356
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Schizophrenia
CompletedNCT05545111
This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can better prevent setbacks and support longer-term stability.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Neurocrine Biosciences
- Condition
- Schizophrenia
CompletedNCT05282186
This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
- Condition
- Schizophrenia
TerminatedNCT05182476
This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 50 Years
- Countries
- Bulgaria, Czech Republic, Serbia, Spain, United States
- Sponsor
- Neurocrine Biosciences
- Condition
- Schizophrenia
CompletedNCT00306475
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Northwestern University
- Condition
- Schizophrenia
CompletedNCT02237235
This study exists to compare options and see whether the medication MMFS-202 offers something meaningfully different. Researchers are trying to understand whether the medication MMFS-202 can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- Northwestern University
- Condition
- Schizophrenia
CompletedNCT05537428
This study exists to explore whether acceptance and commitment therapy, a talking treatment, could improve care and understanding. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Yale University
- Condition
- Schizophrenia
CompletedNCT03183609
This study exists to compare options and see whether blood tests and biological markers offers something meaningfully different. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT05109065
This study exists to learn from real-world information that can show how blood tests and biological markers fits into care. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 18 Years to 40 Years
- Countries
- United States
- Sponsor
- Stanford University
- Condition
- Schizophrenia